MXCT
Maxcyte
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 2
Sell signal 1
consensus rating "Strong Buy"
Revenue Beats Expectation
EPS Below Expectations
Key Stats
--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
About MXCT
Maxcyte, Inc.
A British biotech company pioneering cell therapies for refractory cancers, leveraging its proprietary CAR-T technology
9713 Key West Avenue, Suite 400, Rockville, Maryland 20850
--
MaxCyte, Inc., was incorporated on July 31, 1998 under the laws and regulations of the State of Delaware. The company is a leading commercial cell engineering company focused on providing enabling platform technologies to advance innovative cell-based research and the discovery, development and commercialization of next-generation cell therapies. Over the past two decades, the company has developed and commercialized the proprietary Flow Electroporation platform, which facilitates complex engineering of various cells.
Company Financials
EPS
MXCT has released its 2024 Q4 earnings. EPS was reported at -0.10, versus the expected -0.12, beating expectations. The chart below visualizes how MXCT has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
MXCT has released its 2024 Q4 earnings report, with revenue of 8.69M, reflecting a YoY change of -44.51%, and net profit of -10.60M, showing a YoY change of -100.78%. The Sankey diagram below clearly presents MXCT’s revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
